Literature DB >> 29024491

Surgical morbidity and mortality in patients after microvascular reconstruction for head and neck cancer.

Y-H Joo1, K-J Cho1, J-O Park2, S-Y Kim1, M-S Kim1.   

Abstract

OBJECTIVES: The aim was to evaluate the importance of clinical factors in the prediction of postoperative complications in patients with microvascular reconstruction for head and neck squamous cell cancer (HNSCC).
DESIGN: A retrospective review of case notes was performed.
SETTING: Patients treated at a single institute. PARTICIPANTS: This study included 259 patients with HNSCC treated with radical surgery and microvascular reconstruction between 1993 and 2014. MAIN OUTCOME MEASURES: We allocated the patients to three groups using a preoperative comorbidity score based on risk factors: group A (≥3 risk factors, n = 16), group B (2 risk factors, n = 49) and group C (0 or 1 risk factor, n = 194).
RESULTS: Surgical mortality in this cohort was 1.9% (5 of 259 patients). The preoperative comorbidity score was associated with surgical mortality (P < .001). Pharyngocutaneous fistula (P = .001) and flap compromise (P = .023) were more frequent as preoperative comorbidity score increased. Preoperative comorbidity score (P < .001), advanced age (P = .007), advanced pathologic T stage (P = .028), advanced pathologic N stage (P = .005), preoperative (chemo) radiotherapy (P < .001), history of cardiovascular disease (P = .015) and pulmonary disease (P = .007), and diabetes (P < .001) had significant adverse effects on 5 year disease-specific survival (DSS) in a univariate analysis. The 5-DSS rates of groups A, B and C were 30%, 37% and 70%, respectively. Multivariate analysis showed that preoperative comorbidity score was significantly correlated with 5 year DSS (hazard ratio [HR], 3.56; 95% confidence interval [CI], 1.81-6.99; P < .001 for group A and HR, 1.91; 95% CI, 1.15-3.18; P = .013 for group B compared with group C).
CONCLUSION: Patients with a high preoperative comorbidity score have an increased risk of surgical mortality and morbidity after microvascular reconstruction for HNSCC.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  head and neck neoplasms; morbidity; mortality; reconstructive surgical procedures; squamous cell carcinoma

Mesh:

Year:  2017        PMID: 29024491     DOI: 10.1111/coa.13006

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  6 in total

1.  Impact of comorbidities on perioperative outcomes for carcinoma of oral cavity.

Authors:  R Katna; N Kalyani; S Agarwal; S Singh; A Deshpande; B Bhosale
Journal:  Ann R Coll Surg Engl       Date:  2019-12-16       Impact factor: 1.891

2.  Postoperative Complications of Free Flap Reconstruction in Moderate-Advanced Head and Neck Squamous Cell Carcinoma: A Prospective Cohort Study Based on Real-World Data.

Authors:  Delong Li; Chong Wang; Wei Wei; Bo Li; Huan Liu; Aoming Cheng; Qifang Niu; Zhengxue Han; Zhien Feng
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

3.  Multilevel Associations Between Patient- and Hospital-Level Factors and In-Hospital Mortality Among Hospitalized Patients With Head and Neck Cancer.

Authors:  Eric Adjei Boakye; Nosayaba Osazuwa-Peters; Betty Chen; Miao Cai; Betelihem B Tobo; Sai D Challapalli; Paula Buchanan; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-05-01       Impact factor: 6.223

4.  Four Lessons Learned from Complications in Head and Neck Microvascular Reconstructions and Prevention Strategies.

Authors:  Luís Vieira; Daniel Isacson; Eleonora O F Dimovska; Andres Rodriguez-Lorenzo
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-01-22

5.  Clinical consequences of head and neck free-flap reconstructions in the DM population.

Authors:  Sheng-Nan Chang; Juey-Jen Hwang; Ting-Han Chiu; Chung-Kan Tsao; Jou-Wei Lin
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

6.  Risk Factors for 30-Day Mortality After Head and Neck Microsurgical Reconstruction for Cancer: NSQIP Analysis.

Authors:  Barkat Ali; EunHo Eunice Choi; Venus Barlas; Timothy R Petersen; Nathan G Menon; Nathan T Morrell
Journal:  OTO Open       Date:  2021-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.